Acadia Healthcare Company, Inc. (ACHC) received a bullish endorsement from Jefferies analyst Brian Tanquilut on June 3, 2026, as he upgraded the stock to a “Buy” rating with a price target of $30. This notable shift in sentiment comes at a time when the healthcare services sector is under increased scrutiny, making it an opportune moment for investors to reassess their positions in Acadia.
Recent Price Action
As of its latest trading session, ACHC was priced at $25.73, reflecting a 5.36% increase for the day, or a $1.31 rise. Despite a challenging performance over the past year, during which the stock has suffered a sharp decline of 66.05%, it is important to note that Acadia’s volatility has been somewhat moderated, with a beta of 0.73 indicating less sensitivity to broader market movements. Trading volume was robust at approximately 3.1 million shares, slightly surpassing the average volume of about 2.97 million. This suggests a potential rebounding interest among investors, particularly following the recent analyst recommendation.
[chart type=’price’ value=’ACHC’]
Historical Performance
Over the past 30 days, ACHC has faced headwinds, with a marginal performance decline of 2%. The situation worsened on a quarterly basis, where shares tumbled approximately 41.07%, indicative of broader market pressures and sector-specific challenges. The yearly performance paints an even more sobering picture, with the stock plummeting 66.05% from its previous highs. However, weekly volatility has remained relatively stable at 8.96%, while monthly volatility stood at 5.58%, suggesting potential fluctuations might continue as investors await further clarity.
[chart type=’performance’ value=’ACHC’]
Earnings Analysis
Acadia’s recent earnings report released on April 29, 2026, showcased a significant positive surprise. The company delivered earnings per share (EPS) of $0.37, vastly outpacing analysts’ expectations of $0.28 by about 32.14%. This follows a previous report in February, where the company also exceeded estimates, albeit to a lesser extent. The earlier EPS was reported at $0.07 against an estimate of $0.03, marking a surprising 133.33% upside. Such robust earnings momentum may instill confidence among investors, representing the potential for operational improvements and better-than-expected financial health.
[chart type=’income-bar-chart’ value=’ACHC’]
Analyst Consensus View
The consensus outlook on ACHC appears largely optimistic, with a total of seven analysts reviewing the stock. According to recent data, five analysts have rated it as a “Buy,” while two have opted for a “Hold” rating. No sell recommendations have been issued, suggesting an overall positive sentiment regarding its recovery trajectory. The average price target stands at roughly $29.71, aligning closely with Jefferies’ forecast of $30. This consensus indicates confidence in the stock reaching higher valuations, reflecting improved investor outlook moving forward.
[chart type=’analyst-ratings’ value=’ACHC’]
Stock Grading and Fundamental View
According to the Stocks Telegraph grading system, Acadia Healthcare holds an ST Score of 39, highlighting some underlying concerns regarding its overall financial health and market position. A score in this range typically suggests that, while there might be areas of opportunity, the company also faces challenges that could impact investor confidence and stock performance. This is a critical metric for investors seeking stability and potential growth.
[chart type=’st-cards’ value=’ACHC’]
Conclusion
In conclusion, Acadia Healthcare Company, Inc. (ACHC) presents a compelling case for investors who are willing to engage with a stock that is currently undergoing a transitional phase. The recent upgrade to a “Buy” rating, coupled with a significant positive earnings surprise, positions ACHC as an interesting option for long-term growth investors who can tolerate a degree of risk. However, potential buyers should remain cautious, considering the substantial dips in stock price over the past year and the current ST Score that suggests vigilance is warranted. As the company strives to navigate through its operational challenges, investors may find that Acadia deserves close watching in the upcoming quarters.